Lisa McGregor, MD, PhD

    • 802 Citations
    • 16 h-Index
    19942015
    If you made any changes in Pure, your changes will be visible here soon.

    Fingerprint Dive into the research topics where Lisa McGregor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 2 Similar Profiles
    irinotecan Medicine & Life Sciences
    Neuroblastoma Medicine & Life Sciences
    Pediatrics Medicine & Life Sciences
    Neoplasms Medicine & Life Sciences
    oxaliplatin Medicine & Life Sciences
    Wilms Tumor Medicine & Life Sciences
    Radiotherapy Medicine & Life Sciences
    Maximum Tolerated Dose Medicine & Life Sciences

    Research Output 1994 2015

    • 802 Citations
    • 16 h-Index
    • 33 Article
    • 2 Review article
    • 1 Letter
    2 Citations (Scopus)

    Phase i clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors

    Lam, C. G., Furman, W. L., Wang, C., Spunt, S. L., Wu, J., Ivy, P., Santana, V. M. & McGregor, L. M., Jan 3 2015, In : Journal of Pediatric Hematology/Oncology. 37, 1, p. e13-e18

    Research output: Contribution to journalArticle

    oxaliplatin
    Ifosfamide
    Etoposide
    Maximum Tolerated Dose
    Clinical Trials
    11 Citations (Scopus)

    Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma

    Federico, S. M., Allewelt, H. B., Spunt, S. L., Hudson, M. M., Wu, J., Billups, C. A., Jenkins, J., Santana, V. M., Furman, W. L. & McGregor, L. M., Jan 3 2015, In : Journal of Pediatric Hematology/Oncology. 37, 1, p. e6-e12

    Research output: Contribution to journalArticle

    Neuroblastoma
    Pediatrics
    Neoplasms
    Incidence
    Myelodysplastic Syndromes
    11 Citations (Scopus)

    Phase i dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors

    Brennan, R. C., Furman, W., Mao, S., Wu, J., Turner, D. C., Stewart, C. F., Santana, V. & McGregor, L., Jan 1 2014, In : Cancer Chemotherapy and Pharmacology. 74, 6, p. 1191-1198 8 p.

    Research output: Contribution to journalArticle

    irinotecan
    Pharmacokinetics
    Refractory materials
    Tumors
    Neoplasms
    75 Citations (Scopus)

    Phase I trial of a novel anti-GD2 monoclonal antibody, hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

    Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K. M., Goldberg, J., Hank, J. A., Billups, C. A., Wu, J., Furman, W. L., McGregor, L. M., Otto, M., Gillies, S. D., Handgretinger, R. & Santana, V. M., May 10 2014, In : Journal of Clinical Oncology. 32, 14, p. 1445-1452 8 p.

    Research output: Contribution to journalArticle

    Neuroblastoma
    Monoclonal Antibodies
    Maximum Tolerated Dose
    Pharmacokinetics
    Hypertensive Encephalopathy
    15 Citations (Scopus)

    Repeat nephron-sparing surgery for children with bilateral Wilms tumor

    Kieran, K., Williams, M. A., McGregor, L. M., Dome, J. S., Krasin, M. J. & Davidoff, A. M., Jan 1 2014, In : Journal of pediatric surgery. 49, 1, p. 149-153 5 p.

    Research output: Contribution to journalArticle

    Wilms Tumor
    Nephrons
    Histology
    Recurrence
    Kidney